Literature DB >> 15605207

[Vascular changes in the pathogenesis of systemic sclerosis].

J H W Distler1, J R Kalden, S Gray, O Distler.   

Abstract

Systemic sclerosis (SSc, scleroderma) is a connective tissue disease of unknown etiology. Perivascular inflammatory infiltrates and endothelial apoptosis with an impaired angiogenesis are observed in early stages of the disease, whereas later stages are characterized by an excessive accumulation of extracellular matrix proteins in the skin and various internal organs. Consistent with the ongoing endothelial cell damage, various markers of endothelial cells such as endothelin-1, sICAM-1, s-VCAM-1 and thrombomodulin are found in high levels in the serum of SSc patients. Surprisingly, the vascular endothelial growth factor (VEGF), a potent angiogenic molecule, is overexpressed in the skin of patients with SSc despite insufficient angiogenesis. Interestingly, patients suffering from diffuse SSc and patients without finger tip ulcers show higher VEGF levels compared to age- and sex-matched controls. These results indicate that a controlled overexpression of VEGF might help to protect against the manifestation of ischemic conditions. On the other hand, data from animal models indicate that a long-term, uncontrolled overexpression of VEGF might have paradox effects on the formation of new vessels leading to capillary changes similar to those observed in SSc. In addition to the impaired angiogenesis, defective vasculogenesis might contribute to the vascular symptoms of SSc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605207     DOI: 10.1007/s00393-004-0671-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  17 in total

Review 1.  The molecular control of angiogenesis.

Authors:  Oliver Distler; Michel Neidhart; Renate E Gay; Steffen Gay
Journal:  Int Rev Immunol       Date:  2002 Jan-Feb       Impact factor: 5.311

Review 2.  Non organ based laboratory markers in systemic sclerosis.

Authors:  N J McHugh; O Distler; R Giacomelli; G Riemekasten
Journal:  Clin Exp Rheumatol       Date:  2003       Impact factor: 4.473

Review 3.  Angiogenic and angiostatic factors in the molecular control of angiogenesis.

Authors:  J H W Distler; A Hirth; M Kurowska-Stolarska; R E Gay; S Gay; O Distler
Journal:  Q J Nucl Med       Date:  2003-09

4.  Defective vasculogenesis in systemic sclerosis.

Authors:  Masataka Kuwana; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

5.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma.

Authors:  R Sgonc; M S Gruschwitz; H Dietrich; H Recheis; M E Gershwin; G Wick
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 6.  Immunopathogenesis of systemic sclerosis.

Authors:  B White
Journal:  Rheum Dis Clin North Am       Date:  1996-11       Impact factor: 2.670

7.  Electron microscopy and capillaroscopically guided nailfold biopsy in connective tissue diseases: detection of ultrastructural changes of the microcirculatory vessels.

Authors:  A von Bierbrauer; P Barth; J Willert; C Baerwald; H D Mennel; J A Schmidt
Journal:  Br J Rheumatol       Date:  1998-12

8.  In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay.

Authors:  Miriam Worda; Roswitha Sgonc; Hermann Dietrich; Harald Niederegger; Roy S Sundick; M Eric Gershwin; Georg Wick
Journal:  Arthritis Rheum       Date:  2003-09

9.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.

Authors:  Oliver Distler; Angela Del Rosso; Roberto Giacomelli; Paola Cipriani; Maria L Conforti; Serena Guiducci; Renate E Gay; Beat A Michel; Pius Brühlmann; Ulf Müller-Ladner; Steffen Gay; Marco Matucci-Cerinic
Journal:  Arthritis Res       Date:  2002-08-30

10.  Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).

Authors:  A Scheja; A Akesson; P Geborek; M Wildt; C B Wollheim; F A Wollheim; U M Vischer
Journal:  Arthritis Res       Date:  2001-02-19
View more
  4 in total

1.  [Systemic sclerosis].

Authors:  B A Michel
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

Review 2.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

3.  Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis.

Authors:  Ewa Wielosz; Magdalena Dryglewska; Maria Majdan
Journal:  Clin Rheumatol       Date:  2009-05-13       Impact factor: 2.980

4.  Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway.

Authors:  Mengguo Liu; Ji Yang; Ming Li
Journal:  Clinics (Sao Paulo)       Date:  2015-04       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.